Organon vs BeOne Medicines
Organon reported revenue of $6.2 billion in fiscal 2025, 1.2 times BeOne Medicines' $5.3 billion in fiscal 2025. Organon's revenue fell 2.9% in its latest year, and BeOne Medicines' grew 40.2%. Free cash flow was $538 million at Organon and $942 million at BeOne Medicines.
Side by side
| Organon | BeOne Medicines | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6.2B | $5.3B |
| Revenue growth | −2.9% | 40.2% |
| Revenue growth a year, last 5 years | −1.0% | 76.8% |
| Gross margin | 53.3% | 87.5% |
| Operating margin | — | 8.4% |
| Net margin | 3.0% | 5.4% |
| Free cash flow | $538M | $942M |
| Free cash flow margin | 8.7% | 17.6% |
| Return on capital | 5.3% | 25.8% |
| Net debt to EBITDA | 6.3x | −6.3x |
| Dividends and buybacks | $88M | $0M |
| Change in diluted share count | 0.6% | 7.8% |
| Last close | $13.91 | $399.70 |
| P/E at the last close | 18.1× | — |
| Insider trades, last 12 months | bought $353,086, sold $200,307 | sold $361.1 million |
| Piotroski F-score | 5 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
OrganonBeOne Medicines
Operating margin
Percent of revenue
OrganonBeOne Medicines
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OrganonBeOne Medicines
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Organon and BeOne Medicines pages.